Drug-eluting stents yield better outcomes than bare-metal ones

Nov 19, 2007

Drug-eluting stents are just as safe and effective as traditional bare-metal stents when used in routine clinical practice, according to a new study by researchers at Rhode Island Hospital. Their findings are published in the November 20th issue of the Journal of the American College of Cardiology.

Sometimes known as medication-coated stents, drug-eluting stents are tiny tubes used to open narrowed arteries and slowly release a drug to prevent scar tissue growth. Although they have been universally accepted as more superior than more traditional, bare-metal stents, there is limited data comparing the generalized use of both stents, said lead researcher J. Dawn Abbott, M.D., a cardiologist at Rhode Island Hospital.

“Considering that drug-eluting stents are being used in the vast majority of stent procedures, its reassuring to find that they yield better outcomes than bare-metal stents when used in routine clinical practice,” said Abbott, who’s also an assistant professor of medicine at The Warren Alpert Medical School of Brown University.

Using broad geographic data from the National Heart, Lung and Blood Institute (NHLBI) Dynamic Registry, Abbott and her team compared outcomes for patients who underwent percutaneous coronary intervention – or angioplasty – and were treated with stents. One group received drug-eluting stents while a similar group received bare-metal stents when they were used more broadly before the commercialization of drug-eluting stents. Although separated in time by a few years, no other technologic advances other than drug-eluting stents occurred between recruitment of both groups of patients.

The researchers found that for at least up to one year, the use of drug-eluting stents in standard clinical practice was not associated with any excess risk of death or heart attack compared with bare-metal stents, even in patients with complex heart lesions. The cumulative death and heart attack rate in patients receiving drug-eluting stents was 7.6 percent compared to 8.7 percent in those treated with bare-metal stents.

Patients treated with drug-eluting stents also had a substantial reduction in clinically-driven target vessel revascularization (repeat angioplasty or bypass surgery of the target vessel) compared with patients who received bare-metal stents (5 percent vs. 8.7 percent). Furthermore, the durability of the initial angioplasty was found to be enhanced with drug-eluting stents.

“These findings confirm the safety and effectiveness of drug-eluting stents out to one year, but we are continuing to follow these patients to assess for possible late complications related to the stent implantation,” said senior author David O. Williams, M.D., a cardiologist at Rhode Island Hospital and a professor of medicine at Alpert Medical School.

This analysis compared 1,460 patients enrolled in the NHLBI Dynamic Registry in 2004 who received at least one drug-eluting stent and 1,760 patients who enrolled just before the approval of drug-eluting stents (2001 to 2002) and received at least one bare-metal stent. Researchers looked at lesion characteristics and procedural outcomes and both in-hospital and clinical outcomes after one year. All patients had also undergone angioplasty at selected clinical centers in North America. The study included drug-eluting stents that released either sirolimus or paclitaxel.

Source: Lifespan.org

Explore further: Clipping proteins that package genes may limit abnormal cell growth in tumors

add to favorites email to friend print save as pdf

Related Stories

US northeast braces for flooding after record snow

5 hours ago

Weather forecasters and emergency officials warned Sunday that melting snow would lead to heavy flooding in parts of the US northeast, with hundreds of thousands of people told to brace for fast-rising waters.

How the hummingbird achieves its aerobatic feats

12 hours ago

(Phys.org) —The sight of a tiny hummingbird hovering in front of a flower and then darting to another with lightning speed amazes and delights. But it also leaves watchers with a persistent question: How ...

'Mind the gap' between atomically thin materials

13 hours ago

In subway stations around London, the warning to "Mind the Gap" helps commuters keep from stepping into empty space as they leave the train. When it comes to engineering single-layer atomic structures, minding ...

Recommended for you

Organovo has 3D-printed liver tissue for drug testing

Nov 20, 2014

(Medical Xpress)—The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.